Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial
- PMID: 11551875
- DOI: 10.1161/hc3601.095927
Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial
Abstract
Background: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) study was designed to test whether enalapril achieves greater left ventricular (LV) mass reduction than does a nifedipine gastrointestinal treatment system by a prognostically meaningful degree on a population basis (10 g/m(2)).
Methods and results: An ethnically diverse population of 303 men and women with essential hypertension and increased LV mass at screening echocardiography were enrolled at clinical centers on 4 continents and studied by echocardiography at baseline and after 6- and 12-month randomized therapy. Clinical examination and blinded echocardiogram readings 48 weeks after study entry in an intention-to-treat analysis of 113 enalapril-treated and 122 nifedipine-treated patients revealed similar reductions in systolic/diastolic pressure (-22/12 versus -21/13 mm Hg) and LV mass index (-15 versus -17g/m(2), both P>0.20). No significant between-treatment difference was detected in population subsets defined by monotherapy treatment, sex, age, race, or severity of baseline hypertrophy. Similarly, there was no between-treatment difference in change in velocities of early diastolic or atrial phase transmitral blood flow. More enalapril-treated than nifedipine-treated patients required supplemental treatment with hydrochlorothiazide (59% versus 34%, P<0.001) but not atenolol (27% versus 22%, NS).
Conclusions: Once-daily antihypertensive treatment with enalapril or long-acting nifedipine, plus adjunctive hydrochlorothiazide and atenolol when needed to control blood pressure, both had moderately beneficial and statistically indistinguishable effects on regression of LV hypertrophy.
Similar articles
-
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.Minerva Cardioangiol. 2002 Jun;50(3):169-74. Minerva Cardioangiol. 2002. PMID: 12107398 Review.
-
Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa.Arch Intern Med. 2001 Apr 9;161(7):965-71. doi: 10.1001/archinte.161.7.965. Arch Intern Med. 2001. PMID: 11295959 Clinical Trial.
-
Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial).Am J Cardiol. 1996 Jul 1;78(1):61-5. doi: 10.1016/s0002-9149(96)00228-7. Am J Cardiol. 1996. PMID: 8712120 Clinical Trial.
-
Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension.Am J Hypertens. 1999 Feb;12(2 Pt 1):194-203. doi: 10.1016/s0895-7061(98)00233-7. Am J Hypertens. 1999. PMID: 10090348 Clinical Trial.
-
Changes in left ventricular geometry during antihypertensive treatment.Pharmacol Res. 2018 Aug;134:193-199. doi: 10.1016/j.phrs.2018.06.026. Epub 2018 Jun 26. Pharmacol Res. 2018. PMID: 29959031 Review.
Cited by
-
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial.Drug Des Devel Ther. 2013 Mar 22;7:175-83. doi: 10.2147/DDDT.S42338. Print 2013. Drug Des Devel Ther. 2013. PMID: 23662047 Free PMC article. Clinical Trial.
-
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.J Clin Hypertens (Greenwich). 2008 Mar;10(3):208-14. doi: 10.1111/j.1751-7176.2008.07596.x. J Clin Hypertens (Greenwich). 2008. PMID: 18326961 Free PMC article. Clinical Trial.
-
Discovery and Development of Calcium Channel Blockers.Front Pharmacol. 2017 May 29;8:286. doi: 10.3389/fphar.2017.00286. eCollection 2017. Front Pharmacol. 2017. PMID: 28611661 Free PMC article. Review.
-
Association of Blood Pressure Control Level With Left Ventricular Morphology and Function and With Subclinical Cerebrovascular Disease.J Am Heart Assoc. 2017 Jul 30;6(8):e006246. doi: 10.1161/JAHA.117.006246. J Am Heart Assoc. 2017. PMID: 28757483 Free PMC article.
-
Effects of smoking cessation on central blood pressure and arterial stiffness.Vasc Health Risk Manag. 2011;7:633-8. doi: 10.2147/VHRM.S25798. Epub 2011 Oct 20. Vasc Health Risk Manag. 2011. PMID: 22102787 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous